Becker_1988_Acta.Neurol.Scand.Supplementum_116_19

This paper reviews clinical trials with physostigmine administered to Alzheimer patients using three different routes of administration: oral, i.v. and intracerebroventricular (i.c.v.). It compares results obtained with three different routes by the authors as well as by other authors. Particular emphasis is given to a novel type of physostigmine administration, the i.c.v. route. Advantages and disadvantages, as well as side effects of each route are presented and discussed.